Persistent immune activation in CVID and the role of IVIg in its suppression

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Paquin Proulx, Dominic ^a   Sandberg, Johan K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD4 T cells; CD8 T cells; CVID; Dendritic cells; IgG replacement therapy; Immune activation; iNKT cells; IVIg

Indexed keywords

CD11B ANTIGEN; IMMUNOGLOBULIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COMMON VARIABLE IMMUNODEFICIENCY; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PHAGOCYTOSIS; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY;

EID: 84919478333     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00637     Document Type: Short Survey

References (65)

1. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood (2010) 116(1):7-15. doi: 10.1182/blood-2010-01-254417
2. Salzer U, Unger S, Warnatz K. Common variable immunodeficiency (CVID): exploring the multiple dimensions of a heterogeneous disease. Ann N Y Acad Sci (2012) 1250:41-9. doi:10.1111/j.1749-6632.2011.06377.x
3. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (1999) 92(1):34-48. doi:10.1006/clim.1999.4725
4. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood (2012) 119(7):1650-7. doi:10.1182/blood-2011-09-377945
5. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)-beyond immunodeficiencies and neurology. Clin Exp Immunol (2009) 158(Suppl 1):23-33. doi:10.1111/j.1365-2249.2009.04024.x
6. Schwab I, Lux A, Nimmerjahn F. Reply to-IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol (2014) 14(5):349. doi:10.1038/nri3401-c1
7. von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Kasermann F, et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol (2014) 14(5):349. doi:10.1038/nri3401-c2
8. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 164(Suppl 2):2-5. doi:10.1111/j.1365-2249.2011.04387.x
9. Bjorkstrom NK, Kekalainen E, Mjosberg J. Tissue-specific effector functions of innate lymphoid cells. Immunology (2013) 139(4):416-27. doi:10.1111/imm.12098
10. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 132(3):536-44. doi:10.1016/j.jaci.2013.07.006
11. Aspalter RM, Sewell WA, Dolman K, Farrant J, Webster AD. Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia. Clin Exp Immunol (2000) 121(3):506-14. doi:10.1046/j.1365-2249.2000.01317.x
12. Borregaard N. Neutrophils, from marrow to microbes. Immunity (2010) 33(5):657-70. doi:10.1016/j.immuni.2010.11.011
13. Casulli S, Coignard-Biehler H, Amazzough K, Shoai-Tehrani M, Bayry J, Mahlaoui N, et al. Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficiency. Immunol Res (2014) 60(1):69-76. doi:10.1007/s12026-014-8555-7
14. Casulli S, Topcu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, et al. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One (2011) 6(10):e26469. doi:10.1371/journal.pone.0026469
15. Spahn JH, Kreisel D. Monocytes in sterile inflammation: recruitment and functional consequences. Arch Immunol Ther Exp (Warsz) (2014) 62(3):187-94. doi:10.1007/s00005-013-0267-5
16. Barbosa RR, Silva SP, Silva SL, Tendeiro R, Melo AC, Pedro E, et al. Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin Exp Immunol (2012) 169(3):263-72. doi:10.1111/j.1365-2249.2012.04620.x
17. Siedlar M, Strach M, Bukowska-Strakova K, Lenart M, Szaflarska A, Weglarczyk K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol (2011) 139(2):122-32. doi:10.1016/j.clim.2011.01.002
18. Aukrust P, Muller F, Froland SS. Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency. Clin Exp Immunol (1994) 97(2):232-8. doi:10.1111/j.1365-2249.1994.tb06073.x
19. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 104(8):2441-3. doi:10.1182/blood-2004-04-1325
20. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 101(39):14210-5. doi:10.1073/pnas.0402183101
21. Yong PF, Workman S, Wahid F, Exley A, Webster AD, Ibrahim MA. Selective deficits in blood dendritic cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia but not specific polysaccharide antibody deficiency. Clin Immunol (2008) 127(1):34-42. doi:10.1016/j.clim.2007.12.007
22. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Barreto de Oliveira AK, Kokron CM, et al. IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One (2013) 8(10):e75199. doi:10.1371/journal.pone.0075199
23. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Oliveira AK, Kokron CM, et al. Dysregulated CD1 profile in myeloid dendritic cells in CVID is normalized by IVIg treatment. Blood (2013) 121(24):4963-4. doi:10.1182/blood-2013-04-499442
24. Smed-Sorensen A, Moll M, Cheng TY, Lore K, Norlin AC, Perbeck L, et al. IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa. Blood (2008) 111(10):5037-46. doi:10.1182/blood-2007-07-099549
25. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-autoreactive T cells are a normal component of the human alphabeta T cell repertoire. Nat Immunol (2010) 11(12):1102-9. doi:10.1038/ni.1956
26. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol (2013) 34(2):50-8. doi:10.1016/j.it.2012.08.009
27. Fulcher DA, Avery DT, Fewings NL, Berglund LJ, Wong S, Riminton DS, et al. Invariant natural killer (iNK) T cell deficiency in patients with common variable immunodeficiency. Clin Exp Immunol (2009) 157(3):365-9. doi:10.1111/j.1365-2249.2009.03973.x
28. Carvalho KI, Melo KM, Bruno FR, Snyder-Cappione JE, Nixon DF, Costa-Carvalho BT, et al. Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID). PLoS One (2010) 5(9):e12652. doi:10.1371/journal.pone.0012652
29. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Oliveira AK, Kokron CM, et al. Invariant natural killer T cells in patients with common variable immunodeficiency. J Allergy Clin Immunol (2014) 134(4):989-90. doi:10.1016/j.jaci.2014.06.039
30. Gao Y, Workman S, Gadola S, Elliott T, Grimbacher B, Williams AP. Common variable immunodeficiency is associated with a functional deficiency of invariant natural killer T cells. J Allergy Clin Immunol (2014) 133(5):1420-8. doi:10.1016/j.jaci.2013.10.059
31. Dolcino M, Patuzzo G, Barbieri A, Tinazzi E, Rizzi M, Beri R, et al. Gene expression profiling in peripheral blood mononuclear cells of patients with common variable immunodeficiency: modulation of adaptive immune response following intravenous immunoglobulin therapy. PLoS One (2014) 9(5):e97571. doi:10.1371/journal.pone.0097571
32. Aukrust P, Hestdal K, Lien E, Bjerkeli V, Nordoy I, Espevik T, et al. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis (1997) 176(4):913-23. doi:10.1086/516510
33. Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, Miedema F, et al. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses (2007) 23(11):1348-53. doi:10.1089/aid.2006.0210
34. Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J Exp Med (2014) 211(10):2033-45. doi:10.1084/jem.20140039
35. Carter CR, Aravind G, Smalle NL, Cole JY, Savic S, Wood PM. CVID patients with autoimmunity have elevated T cell expression of granzyme B and HLA-DR and reduced levels of Treg cells. J Clin Pathol (2013) 66(2):146-50. doi:10.1136/jclinpath-2012-201046
36. Genre J, Errante PR, Kokron CM, Toledo-Barros M, Camara NO, Rizzo LV. Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with common variable immunodeficiency: a link to autoimmunity? Clin Immunol (2009) 132(2):215-21. doi:10.1016/j.clim.2009.03.519
37. Melo KM, Carvalho KI, Bruno FR, Ndhlovu LC, Ballan WM, Nixon DF, et al. A decreased frequency of regulatory T cells in patients with common variable immunodeficiency. PLoS One (2009) 4(7):e6269. doi:10.1371/journal.pone.0006269
38. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clin Drug Investig (2011) 31(5):299-307. doi:10.1007/BF03256928
39. Arandi N, Mirshafiey A, Jeddi-Tehrani M, Abolhassani H, Sadeghi B, Mirminachi B, et al. Evaluation of CD4+CD25+FOXP3+ regulatory T cells function in patients with common variable immunodeficiency. Cell Immunol (2013) 281(2):129-33. doi:10.1016/j.cellimm.2013.03.003
40. Hel Z, Huijbregts RP, Xu J, Nechvatalova J, Vlkova M, Litzman J. Altered serum cytokine signature in common variable immunodeficiency. J Clin Immunol (2014) 34(8):971-8. doi:10.1007/s10875-014-0099-z
41. Aubin E, Lemieux R, Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood (2010) 115(9):1727-34. doi:10.1182/blood-2009-06-225417
42. Paquin-Proulx D, Aubin E, Lemieux R, Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol (2010) 135(3):422-9. doi:10.1016/j.clim.2010.01.001
43. Aubin E, Proulx DP, Trepanier P, Lemieux R, Bazin R. Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation. Clin Immunol (2011) 141(3):273-83. doi:10.1016/j.clim.2011.06.009
44. Padet L, St-Amour I, Aubin E, Bazin R. Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells? Clin Exp Immunol (2011) 166(3):352-60. doi:10.1111/j.1365-2249.2011.04476.x
45. Padet L, Bazin R. IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators. Immunol Lett (2013) 150(1-2):54-60. doi:10.1016/j.imlet.2012.12.011
46. Marashi SM, Raeiszadeh M, Workman S, Rahbar A, Soderberg-Naucler C, Klenerman P, et al. Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. J Allergy Clin Immunol (2011) 127(6):1385-93. doi:10.1016/j.jaci.2011.04.001
47. Marashi SM, Raeiszadeh M, Enright V, Tahami F, Workman S, Chee R, et al. Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. J Allergy Clin Immunol (2012) 129(5):1349-56. doi:10.1016/j.jaci.2012.02.011
48. Young GR, Eksmond U, Salcedo R, Alexopoulou L, Stoye JP, Kassiotis G. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature (2012) 491(7426):774-8. doi:10.1038/nature11599
49. Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation (2011) 92(3):267-70. doi:10.1097/TP.0b013e318224115e
50. St-Amour I, Laroche A, Bazin R, Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol (2009) 133(1):52-60. doi:10.1016/j.clim.2009.06.005
51. van de Ven AA, Janssen WJ, Schulz LS, van Loon AM, Voorkamp K, Sanders EA, et al. Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies. J Clin Immunol (2014) 34(8):962-70. doi:10.1007/s10875-014-0087-3
52. Litzman J, Nechvatalova J, Xu J, Ticha O, Vlkova M, Hel Z. Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. Clin Exp Immunol (2012) 170(3):321-32. doi:10.1111/j.1365-2249.2012.04655.x
53. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 179(4):859-70. doi:10.1086/314660
54. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 5(10):e203. doi:10.1371/journal.pmed.0050203
55. Hamlyn E, Fidler S, Stohr W, Cooper DA, Tambussi G, Schechter M, et al. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS (2014) 28(6):869-74. doi:10.1097/QAD.0000000000000155
56. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 200(6):973-83. doi:10.1086/605447
57. Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 27(9):1433-41. doi:10.1097/QAD.0b013e32835f6b0c
58. Varzaneh FN, Keller B, Unger S, Aghamohammadi A, Warnatz K, Rezaei N. Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets-a review of the current knowledge. J Clin Immunol (2014) 34(5):524-43. doi:10.1007/s10875-014-0053-0
59. Shulzhenko N, Morgun A, Hsiao W, Battle M, Yao M, Gavrilova O, et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med (2011) 17(12):1585-93. doi:10.1038/nm.2505
60. Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, Laeyendecker O, et al. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS One (2011) 6(4):e18779. doi:10.1371/journal.pone.0018779
61. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr., Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 335(18):1350-6. doi:10.1056/NEJM199610313351803
62. Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood (2006) 107(8):3081-3. doi:10.1182/blood-2005-09-3636
63. Kuylenstierna C, Snyder-Cappione JE, Loo CP, Long BR, Gonzalez VD, Michaelsson J, et al. NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection. Scand J Immunol (2011) 73(2):141-6. doi:10.1111/j.1365-3083.2010.02484.x
64. Cunningham-Rundles C, Bodian C, Ochs HD, Martin S, Reiter-Wong M, Zhuo Z. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol (2001) 100(2):181-90. doi:10.1006/clim.2001.5052
65. Ciccocioppo R, Comoli P, Gallia A, Basso S, Baldanti F, Corazza GR. Autologous human cytomegalovirus-specific cytotoxic T cells as rescue therapy for ulcerative enteritis in primary immunodeficiency. J Clin Immunol (2014) 34(6):681-5. doi:10.1007/s10875-014-0060-1